MarketPulse

clinical trial safety concerns

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Class Action Over Hidden Safety Issues

Rosen Law Firm urges Soleno Therapeutics investors with $100K+ losses to join securities lawsuit alleging concealed DCCR drug safety concerns. Lead plaintiff deadline: May 5, 2026.
EOSENUAINUAIWSLNOinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over DCCR Safety Disclosures

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors have until May 5, 2026 deadline to join lawsuit.
SLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Soleno Therapeutics Faces Federal Securities Lawsuit Over Drug Safety Misrepresentations

Federal class action filed against $SLNO over alleged safety misrepresentations of DCCR drug. Stock fell 39% after safety revelations; investor deadline May 5, 2026.
SLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over PWS Drug Safety Claims

Securities class action filed against $SLNO over alleged false statements regarding safety risks in Phase 3 trial for Prader-Willi syndrome treatment. Lead plaintiff deadline: May 5, 2026.
SLNOsecurities class actionlead plaintiff deadline
BenzingaBenzinga··The Law Offices Of Frank R. Cruz

SLNO Shareholders Sue Over Alleged Safety Disclosure Failures in PWS Drug Trial

Soleno Therapeutics faces securities fraud lawsuit alleging failure to disclose safety concerns about DCCR drug candidate between March 2025 and November 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Safety Risks in DCCR Trial

Rosen Law Firm files class action against Soleno Therapeutics for allegedly concealing fluid retention safety concerns in DCCR clinical trials, affecting drug viability.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Soleno Therapeutics Faces Class Action Over DCCR Safety Claims as Stock Plummets 27%

Robbins LLP launches class action against $SLNO over alleged investor deception regarding DCCR drug safety and efficacy for Prader-Willi syndrome treatment.
EOSEDRVNSLNOclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Fraud Probe Over Undisclosed Safety Data

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.
SLNOstock declinesecurities class action